Download biomedica product list
Periostin – a prognostic biomarker in breast cancer
Periostin is a soluble extracellular matrix protein that plays a role in bone formation and has been linked to the development of various cancers, including breast cancer. It is secreted in the tumor environment mostly by cancer associated fibroblasts promoting the progression of cancer which includes cell survival, metastasis and also chemoresistance.
Periostin – a prognostic biomarker in breast cancer
The prognostic value of serum Periostin was investigated in a cohort of 509 non metastatic breast cancer patients. The results demonstrated the importance of Periostin in breast cancer and showed that serum Periostin is a prospective indicator for disease prognosis, regardless of the existence of micrometastases. Read more: High serum levels of periostin are associated with a poor survival in breast cancer.
Human serum Periostin levels were measured with the BIOMEDICA PERIOSTIN ELISA.
Periostin ELISA (cat. no. BI-20433)
-
- Low sample volume – 10 µl sample / well
- For human serum/plasma/cell culture supernatants
- High quality assay – validation following international guidelines
- All reagents included – 7 ready to use calibrators and 2 controls
- Numerous citations using the Biomedica Periostin ELISA
example of a BIOMEDICA ELISA assay kit with color-coded reagents, ready to use pre-diluted calibrators/standards and 2 (high/low) kit controls
The full characterization of the Periostin ELISA assay has been published in:
Characterization of a sandwich ELISA for the quantification of all human periostin isoforms. Gadermaier E et al., .J Clin Lab Anal. 2018, 32(2):e22252. doi: 10.1002/jcla.22252.
Also available: Mouse Periostin ELISA (cat. no. BI-20433MS)
- Low sample volume – ≤ 5 µl / well
- For serum/plasma/cell culture supernatants
All ELISA kits are developed and manufactured by BIOMEDICA-Vienna/Austria
Related publications
High serum levels of periostin are associated with a poor survival in breast cancer. Rachner TD, Göbel A, Hoffmann O, Erdmann K, Kasimir-Bauer S, Breining D, Kimmig R, Hofbauer LC, Bittner AK. Breast Cancer Res Treat. 2020 Apr;180(2):515-524. doi: 10.1007/s10549-020-05570-0. Epub 2020 Feb 10. PMID: 32040688.
Periostin gene expression in neu-positive breast cancer cells is regulated by a FGFR signaling cross talk with TGFβ/PI3K/AKT pathways. Labrèche C, Cook DP, Abou-Hamad J, Pascoal J, Pryce BR, Al-Zahrani KN, Sabourin LA. Breast Cancer Res. 2021 Nov 22;23(1):107. doi: 10.1186/s13058-021-01487-8. PMID: 34809697; PMCID: PMC8607680.
Periostin Exon-21 Antibody Neutralization of Triple-Negative Breast Cancer Cell-Derived Periostin Regulates Tumor-Associated Macrophage Polarization and Angiogenesis. Fujikawa T, Sanada F, Taniyama Y, Shibata K, Katsuragi N, Koibuchi N, Akazawa K, Kanemoto Y, Kuroyanagi H, Shimazu K, Rakugi H, Morishita R.Cancers (Basel). 2021 Oct 11;13(20):5072. doi: 10.3390/cancers13205072. PMID: 34680221; PMCID: PMC8533925.
The Role of Extracellular Matrix Proteins in Breast Cancer. Lepucki A, Orlińska K, Mielczarek-Palacz A, Kabut J, Olczyk P, Komosińska-Vassev K. J Clin Med. 2022 Feb 25;11(5):1250. doi: 10.3390/jcm11051250. PMID: 35268340; PMCID: PMC8911242.